StockData
SI-BONE, Inc. logo

SI-BONE, Inc. (SIBN) company profile

SIBNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3042% above fair value
$23.16−0.25 (-1.07%)

Close on Nov 17, 2026Market cap $1.04BP/E –Yield 0.00%

About Si-Bone

Surgical & Medical Instruments & Apparatus, SIC 3841

The medical device company develops procedural implants and surgical instruments for patients with compromised bone, focusing on sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. Its main offerings include the iFuse line of titanium and 3D-printed implants, such as iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse TORQ TNT, alongside human bone allograft products. The company's customer base consists of healthcare professionals, primarily orthopedic spine surgeons, neurosurgeons, orthopedic trauma surgeons, and interventional spine physicians.

The company markets its products in the United States and internationally. In the United States, its commercial organization covers 16 sales regions staffed by 89 territory sales managers, 83 clinical specialists, and 320 third-party sales agents. Internationally, it distributes through 11 direct sales representatives and 28 third-party sales agents, with commercial sales in 38 countries. Additionally, surgeons have conducted more than 140,000 procedures using its products since 2009.

Summary of the business section of Si-Bone's latest annual report, written by StockData.

Company profile

Company

Legal name
SI-BONE, Inc.
Founded
2008
Headquarters
San Jose, CA
Address
88 W. Plumeria Drive 95134
Phone
(408) 207-0700
Employees
376, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
SIBN
Exchange
Nasdaq
IPO date
Oct 18, 2018
Shares outstanding
45M, Jul 29, 2026
Public float
$800.00M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1459839
CUSIP
825704109
ISIN
US8257041090
FIGI
BBG001J414K6
Share class FIGI
BBG001V0GNP7
LEI
549300J8JGYVJJHV9C31
EIN
26-2216351

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Laura FrancisChief Executive Officer, Director672,385
Michael A. PisetskySVP, Ops & Adm/Chief Legal Ofr204,611
Anshul MaheshwariChief Op & Financial Officer211,250
Jeffrey W. DunnDirector97,130
Jeryl L. HillemanDirector43,772
Timothy E. Davis JRDirector76,679
Thomas A. WestDirector37,947
John Gordon FreundDirector146,025
Mika NishimuraDirector43,673
Greg K. HinckleyDirector105,135
Daniel W. WolfDirector25,857

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr.Dunn
$0$0$2.53M$66$123
FY2025
Ms.Francis
$7.45M$10.00M$2.53M$66$123
FY2024
Mr.Dunn
$0$0$2.52M$47$114
FY2024
Ms.Francis
$7.09M$2.49M$2.52M$47$114
FY2023
Mr.Dunn
$0$0$1.96M$70$105
FY2023
Ms.Francis
$3.71M$7.09M$1.96M$70$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payTotalvs. prior year
Laura A. Francis
Chief Executive Officer
$685.00K$6.04M$729.53K$7.45M+5%
Anshul Maheshwari
Chief Operating Officer & Chief Financial Officer
$496.67K$1.98M$317.37K$2.79M+13%
Anthony J. Recupero
Former President, Commercial Operations
$500.58K$1.54M$399.84K$2.45M-5%
Michael A. Pisetsky
Chief Business & Legal Affairs Officer
$493.41K$1.61M$262.74K$2.36M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 18, 2018
Offer price
$15.00
Securities offered
7,200,000
Gross proceeds
$108.00M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 16, 2019

“The initial public offering price per share is $15.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 376 employees, including sales and marketing, product development, general administrative and accounting, both domestically and internationally.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?